Filter zurücksetzen
Stichworte
Behandlungsbedürftigkeit, Begutachtung ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
    1. 7.1. Anästhesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynäkologie/Geburtshilfe
    1. 7.6. Innere Medizin
      1. Hämatologie
      1. Infektiologie
      1. Kardiologie/Angiologie
      1. Pneumologie
      1. Gastroenterologie
      1. Nephrologie
      1. Endokrinologie/Stoffwechsel
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Augenheilkunde
    1. 7.9. Palliativmedizin
    1. 7.10. Pathologie/Rechtsmedizin
    1. 7.11. Kinderheilkunde
    1. 7.12. Psychiatrie/Psychosomatik
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Allgemein-/Viszeralchirurgie
      1. Neurochirurgie
      1. Plastische Chirurgie
      1. Herz-/Thoraxchirurgie
      1. Unfallchirurgie/Orthopädie
      1. Gefäßchirurgie
    1. 7.15. Urologie
    1. 7.16. Zahnmedizin/MKG
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

371 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Urinary Bladder, Overactive NCT02385500

- 24.07.19 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Fesoterodine on Urgency Episodes in Parkinson's Disease Population; ODM derived from: https://clinicaltrials.gov/show/NCT02385500

Eligibility DRKS00003516 NCT01374789 Urinary Bladder Cancer - Eligibility

- 20.09.21 - 1 Formular, 2 Itemgruppen, 39 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01374789

Eligibility Bladder Cancer NCT01954173

- 18.08.19 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Adjuvant Radiation for High Risk Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01954173

Eligibility Bladder Cancer NCT00389155

- 04.10.17 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00389155

Eligibility Bladder Neoplasms NCT00001381

- 10.01.16 - 1 Formular, 1 Itemgruppe, 15 Datenelemente, 1 Sprache
Itemgruppe: Criteria
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder; ODM derived from: https://clinicaltrials.gov/show/NCT00001381

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 17.09.21 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion criteria, Exclusion criteria
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Eligibility Bladder Dysfunction in MS NCT00913510

- 03.09.18 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction; ODM derived from: https://clinicaltrials.gov/show/NCT00913510 Sponsor: Wellspect HealthCare Information provided by (Responsible Party): Wellspect HealthCare Principal Investigator: Clare Fowler, Prof. University College, London

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 11.12.13 - 1 Formular, 2 Itemgruppen, 7 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00246974

Eligibility DRKS00004052 NCT00661609 Advanced Bladder Cancer - Eligibility

- 06.12.13 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

Eligibility Solid Tumors, NSCLC, Biliary and Bladder Cancer NCT02240238

- 01.10.20 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02240238

Bladder Cancer NCT00014534 Treatment - CALGB: 90104 Eligibility Checklist - 2169226v3.0 - CALGB: 90104 Eligibility Checklist

- 09.01.15 - 1 Formular, 1 Itemgruppe, 36 Datenelemente, 1 Sprache
Itemgruppe: CCRR MODULE
CALGB: 90104 Eligibility Checklist Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE19FD2A-E369-6ABF-E034-0003BA12F5E7

Eligibility Urinary Problems NCT02220829

- 01.07.16 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02220829

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video